Goran Rakocevic, MD

Goran Rakocevic, MD

Contact Dr. Rakocevic

901 Walnut Street
Suite 400
Philadelphia, PA 19107

(215) 955-7952
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome
  2. Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: Does abnormal jitter predict response to treatment?
  3. Propofol as a Risk Factor for ICU-Acquired Weakness in Septic Patients with Acute Respiratory Failure
  4. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  5. Severe acute inflammatory demyelinating polyradiculoneuropathy with persistent weakness associated with tumor-like nerve root enlargement
  6. Lower extremity peak force and gait kinematics in individuals with inclusion body myositis
  7. Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis
  8. Paraplegia following lumbosacral steroid epidural injections
  9. Are repeated single-limb heel raises and manual muscle testing associated with peak plantar-flexor force in people with inclusion body myositis?
  10. Stiff person syndrome improvement with chemotherapy in a patient with cutaneous t cell lymphoma
  11. Pearls and oy-sters: Neurosyphilis presenting as mesial temporal encephalitis
  12. Reply
  13. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue
  14. Autoimmune stiff person syndrome and related myelopathies: Understanding of electrophysiological and immunological processes
  15. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity
  16. Atypical clinically diagnosed stiff-person syndrome response to dantrolene-a refractory case
  17. Reply: Comment on alemtuzumab and inclusion body myositis
  18. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy
  19. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
  20. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis